Wells Fargo & Company Forecasts Strong Price Appreciation for Bausch + Lomb (NYSE:BLCO) Stock

Bausch + Lomb (NYSE:BLCO) had its target price raised by research analysts at Wells Fargo & Company from $17.00 to $18.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 1.25% from the company’s current price.

A number of other equities analysts have also recently issued reports on BLCO. Citigroup restated a “buy” rating on shares of Bausch + Lomb in a report on Thursday. Barclays set a $20.00 price target on Bausch + Lomb in a research note on Thursday. The Goldman Sachs Group reiterated a “neutral” rating and issued a $19.00 target price on shares of Bausch + Lomb in a report on Friday, January 9th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $18.00 price target on shares of Bausch + Lomb in a research report on Thursday. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $19.00 target price (up previously from $18.00) on shares of Bausch + Lomb in a research report on Thursday, October 30th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.85.

Bausch + Lomb Price Performance

Shares of NYSE:BLCO traded up $0.11 during trading on Thursday, reaching $17.78. The stock had a trading volume of 97,270 shares, compared to its average volume of 382,027. The business has a fifty day moving average price of $17.04 and a 200-day moving average price of $15.81. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.51. The stock has a market cap of $6.30 billion, a PE ratio of -20.43, a PEG ratio of 1.03 and a beta of 0.61. Bausch + Lomb has a 1-year low of $10.45 and a 1-year high of $17.96.

Bausch + Lomb (NYSE:BLCO) last issued its earnings results on Wednesday, February 18th. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.03). Bausch + Lomb had a negative net margin of 6.13% and a positive return on equity of 2.42%. The firm had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.38 billion. During the same period in the previous year, the firm earned $0.25 EPS. The firm’s revenue was up 9.8% on a year-over-year basis. On average, equities analysts forecast that Bausch + Lomb will post 0.74 earnings per share for the current fiscal year.

Institutional Trading of Bausch + Lomb

A number of institutional investors and hedge funds have recently made changes to their positions in BLCO. Oaktree Capital Management LP acquired a new position in shares of Bausch + Lomb during the second quarter worth approximately $32,801,000. Glenview Capital Management LLC raised its position in Bausch + Lomb by 210.8% in the 2nd quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock worth $20,216,000 after purchasing an additional 1,053,855 shares during the last quarter. Davidson Kempner Capital Management LP bought a new position in Bausch + Lomb in the 3rd quarter worth approximately $14,776,000. Woodline Partners LP lifted its holdings in Bausch + Lomb by 175.3% during the 3rd quarter. Woodline Partners LP now owns 861,053 shares of the company’s stock worth $12,976,000 after buying an additional 548,230 shares in the last quarter. Finally, Goldentree Asset Management LP boosted its position in Bausch + Lomb by 14.9% in the 2nd quarter. Goldentree Asset Management LP now owns 2,583,185 shares of the company’s stock valued at $33,524,000 after buying an additional 334,916 shares during the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Revenue topped estimates and management reiterated full-year revenue guidance of roughly $5.4B–$5.5B, supporting growth expectations and helping shares rise despite the EPS miss. Read More.
• Positive Sentiment: Company framed the quarter as part of a “record year” and signaled a push toward profitable growth on the conference call — messaging that reassures investors focused on margin recovery and sustainable revenue expansion. Read More.
• Positive Sentiment: Management highlighted product innovation initiatives (CEO promoted a new contact-lens technology) and internal incentives tied to AI literacy, which investors may view as long-term catalysts for differentiation and efficiency. Read More. Read More.
• Neutral Sentiment: Stifel Nicolaus maintained a Hold rating on BLCO — a sign of mixed analyst views that can temper volatility but not strongly move consensus. Read More.
• Neutral Sentiment: Full earnings call transcripts and recaps are available for detail on segment performance and margin drivers; these are useful for investors digging into the drivers behind the top-line beat. Read More. Read More.
• Negative Sentiment: EPS missed consensus ($0.32 vs. $0.35) and the company reported a negative net margin for the quarter, which raises near-term profitability concerns and explains part of analyst caution. Read More.
• Negative Sentiment: Bank of America reiterated a Sell rating and set a $15 price target, citing structural and margin headwinds — a high-profile negative analyst view that could cap upside until margins visibly improve. Read More.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.